SCHEMBL2867604

SCHEMBL2867604

CC(C)CCOc1ccc(-n2nc3c(c2N)c(=O)[nH]c2cc(OCCCN4CCOCC4)ccc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.43
PDGFRB P09619 1/20 0.43
KDR P35968 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MAOA P21397 1/20 0.42
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
HRH3 Q9Y5N1 5/20 0.40
MAPK1 P28482 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
HTR2A P28223 1/20 0.40
SCN1A P35498 1/20 0.40
HTR2B P41595 1/20 0.40
KCNH2 Q12809 1/20 0.40
SCN2A Q99250 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861337 0.91 KDM4E (0.50) FGFR1PDGFRBKDRKDM4EMAOA
SCHEMBL2865177 0.89 FGFR1 (0.45) FGFR1PDGFRBKDRKDM4EMAOA
SCHEMBL2857971 0.88 FGFR1 (0.48) FGFR1PDGFRBKDRKDM4EMAOA
SCHEMBL2866809 0.87 MCHR1 (0.51) FGFR1PDGFRBKDRKDM4EKMT2A
SCHEMBL2861595 0.86 FGFR1 (0.43) FGFR1PDGFRBKDRKDM4EMAOA
SCHEMBL2861085 0.86 MAOA (0.42) FGFR1PDGFRBKDRKDM4EMAOA
SCHEMBL2870417 0.82 PDGFRB (0.43) FGFR1PDGFRBKDRKDM4EMAOA
SCHEMBL2868581 0.81 KDM4E (0.49) FGFR1PDGFRBKDRKDM4EMAOA
SCHEMBL2864303 0.81 FGFR1 (0.48) FGFR1PDGFRBKDRKDM4EHRH3
SCHEMBL2868766 0.81 KDM4E (0.51) FGFR1PDGFRBKDRKDM4EMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 FGFR1 201/4885PDGFRB 375/4885KDR 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.